{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:33:26Z","timestamp":1790526806168,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T00:00:00Z","timestamp":1466380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Dasatinib was approved at 100\u00a0mg once daily for imatinib\u2010resistant or \u2010intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180\u2010034 (NCT00123474) study. Here we present the final 7\u2010year analysis of this pivotal study, the longest follow\u2010up to date of any second\u2010generation BCR\u2013ABL1 tyrosine kinase inhibitor (TKI). Patients (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>670) with imatinib\u2010resistant or \u2010intolerant CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a greater proportion in the 100\u00a0mg once daily arm remaining on therapy. Seven\u2010year rates for major molecular response (MMR), progression\u2010free survival (PFS), and overall survival (OS) were similar across doses; MMR, PFS, and OS results were 46, 42, and 65% at 100\u00a0mg once daily, respectively. Improved PFS and OS rates were reported in patients who achieved <jats:italic>BCR\u2013ABL1<\/jats:italic> \u226410% at 3 and 6\u00a0months. No new safety signals were identified. The incidence of drug\u2010related pleural effusion was 28% at 100\u00a0mg once daily and 35% at the other three dose groups. Incidence of drug\u2010related pulmonary hypertension and pulmonary arterial hypertension remained low (\u22643% across all doses). Arterial ischemic events occurred in \u22644% of patients across all doses. These data support the long\u2010term efficacy and well\u2010established safety profile of dasatinib for patients with imatinib\u2010resistant or \u2010intolerant CML in chronic phase. Am. J. Hematol. 91:869\u2013874, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24423","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T18:59:14Z","timestamp":1463684354000},"page":"869-874","source":"Crossref","is-referenced-by-count":164,"title":["Dasatinib in imatinib\u2010resistant or \u2010intolerant chronic\u2010phase, chronic myeloid leukemia patients: 7\u2010year follow\u2010up of study CA180\u2010034"],"prefix":"10.1002","volume":"91","author":[{"given":"Neil P.","family":"Shah","sequence":"first","affiliation":[{"name":"UCSF School of Medicine San Francisco  California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[{"name":"H\u00f4pital Andr\u00e9 Mignot and Universit\u00e9 Versailles Saint\u2010Quentin\u2010en\u2010Yvelines Versailles France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[{"name":"Saint Louis Hospital Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"University of Texas M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Milone","sequence":"additional","affiliation":[{"name":"Hospital Italiano De La Plata La Plata Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Healey","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"University of Texas M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Jena Jena Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094045"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs sti571 (IRIS) 8\u2010year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib clinically [Abstract]","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"e_1_2_9_6_1","volume-title":"Sprycel (dasatinib) [prescribing Information]","year":"2015"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"e_1_2_9_9_1","unstructured":"National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0. 2006. Available at:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.812034"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-013-1488-z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.156"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24325"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.04.005"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383711"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24423","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T12:48:49Z","timestamp":1695559729000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,20]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/ajh.24423"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24423","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,20]]}}}